Validity of the Psycho-Oncology Screening Tool (POST).

Identifying cancer patients who are experiencing psychosocial challenges during the early phase of oncology treatment can prevent escalating patient distress. Standardized screening methods allow the medical team to identify those at high risk for poor adjustment. The purpose of this study was to provide preliminary psychometric evidence for a brief, self-administered screening instrument, the Psycho-Oncology Screening Tool (POST), designed to evaluate emotional and physical distress, depressive symptoms, and social concerns.

Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function.

Studies published from 1980 through 2004, which explored intelligence and executive function outcomes in early-treated PKU, were included in the present meta-analysis. The objective of this study was to examine the degree of difference between early-treated PKU and unaffected control groups (primarily non-familial controls), known as effect size, for various components of measured intelligence (i.e.